Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: A prospective study by AIDS clinical trials group 5170

Daniel J. Skiest, Zhaohui Su, Diane V. Havlir, Kevin R. Robertson, Robert W. Coombs, Pat Cain, Tianna Peterson, Amy Krambrink, Nasreen Jahed, Deborah McMahon, David M. Margolis, Tianna Petersen, Nancy Mantz, Michele Downing, Beverly Sha, Jessica Shore, Sylvia Stoudt, Debbie Slamowitz, Linda Meixner, Susan CahillPeter Frame, Michelle Saemann, Alexandra Nesbitt, Joseph J. Eron, Timothy Wilkin, Todd Stroberg, Charles Gonzalez, Margarita Vasquez, Ann C. Collier, Shelia Dunaway, Karen T. Tashima, Pamela Poethke, Ian Frank, Joyce Okawa, Eric S. Daar, Sadia Shaik, Donna Mildvan, Ronald D'Amico, William A. O'Brien, Gerianne Casey, Connie A. Funk, Luis M. Mendez, Kimberly Gray, Ge Youl Kim, Jane Reid, Carol Greisberger, Winston Cavert, Christine Fietzer, Nathan Thielman, Lee McClurkin, Deborah K. O'Connor, Mitchell Goldman

Research output: Contribution to journalArticlepeer-review

59 Scopus citations

Abstract

Background. We sought to determine the safety of treatment interruption (TI) and to identify parameters that would define patients with human immunodeficiency virus (HIV) for whom TI is safer. Methods. AIDS Clinical Trials Group 5170 was a multicenter, 96-week-long, prospective study of HIV-infected patients receiving antiretroviral therapy (ART) who had CD4+ cell counts >350 cells/mm3 and who underwent TI. Results. A total of 167 patients were enrolled. The median nadir in CD4+ cell count was 436 cells/mm3. The initial decrease (i.e., during the first 8 weeks) in CD4+ cell count after ART interruption was 20 cells/mm 3/week; the subsequent decrease was 2.0 cells/mm3/week until week 96. Both the CD4+ cell count before enrollment and the increase in CD4+ cell count during ART predicted early decrease; later decrease was predicted by the level of interleukin-7 at enrollment. A Centers for Disease Control and Prevention (CDC) diagnosis of a category B or C event was made for 2 and 2 patients, respectively (all had CD4+ cell counts >350 cells/mm3). At week 96, 17 patients had CD4 + cell counts ≤250 cells/mm3, and 46 patients had resumed ART; 5 patients died (unrelated to HIV or acquired immunodeficiency syndrome). In a multivariate analysis, a higher nadir in CD4+ cell count (>400 cells/mm3), a lower HIV load (<50 copies/mL) at the time of TI, and an HIV load ≤22,000 copies/mL before ART predicted a longer time to the primary end point (CDC category B or C event, death, CD4+ cell count ≤250 cells/mm3, or resumption of ART). Conclusion. Disease progression after TI was low in this cohort. A higher nadir in CD4 + cell count, a lower HIV load before ART, and an HIV load ≤50 copies/mL at the time of TI predicted a longer time to the primary end point.

Original languageEnglish
Pages (from-to)1426-1436
Number of pages11
JournalJournal of Infectious Diseases
Volume195
Issue number10
DOIs
StatePublished - 15 May 2007
Externally publishedYes

Fingerprint

Dive into the research topics of 'Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: A prospective study by AIDS clinical trials group 5170'. Together they form a unique fingerprint.

Cite this